Translational Biomarker Core

翻译生物标记物核心(TBC)摘要 TBC是环境卓越中心暴露生物学计划的关键组成部分 《战略愿景》中描述的毒理学(CEET)。核心衡量暴露和影响的生物标志物， 疾病的发生和发展，以及环境病因学疾病的治疗反应。TBC 使用基于严格的质谱学(MS)的方法在基于细胞培养的基础上识别生物标志物 模型，在动物模型中，在人群和患者队列中，可以在综合性 健康科学设施核心。被测量的分析物是小的生物分子、蛋白质以及靶向和 非靶向代谢物作为“曝光组”的报告者。TBC认识到，有必要将 生物标志物的表型变化与转录组的变化或遗传变异有关，这是 通过CEET信息学核心执行的数据集成实现。基因组、蛋白质组的整合 代谢组学生物标记物提供了提供新的诊断和预后指标的希望，这些指标可以 用于个人精准环境医学(PREEM)。TBC配备了 最新的液-质联用、超性能液-质联用和超高效液-质联用 高分辨率的质谱仪。许多分析方法使用稳定同位素稀释LC-MS作为金标准 精密度和准确度，而且许多化验是世界其他地方无法进行的。世界银行的目标是 核心是(I)从模型系统和在生物流体中分析暴露和影响的生物标记物 人口队列和患者；(2)提供发现和靶向蛋白质组学方面的服务 代谢组学；(Iii)为CEET研究人员开发新的分析方法，并将这些分析转化为常规核心分析 为其他CEET调查员提供服务；以及(4)为希望开展自己的调查的最终用户提供培训 分析。

Translational Biomarker Core (TBC) Abstract The TBC is a key component of the exposure biology program of the Center of Excellence in Environmental Toxicology (CEET) described in the Strategic Vision. The Core measures biomarkers of exposure and effect, disease onset and progression, and therapeutic response for diseases of environmental etiology. The TBC employs rigorous mass spectrometry (MS)-based methodology to identify biomarkers in cell-culture based models, in animal models and in population and patient cohorts that may be identified in the Integrative Health Sciences Facility Core. Analytes measured are small biomolecules, proteins, as well as targeted and untargeted metabolomes as reporters of the "exposome". The TBC recognizes that the need to relate phenotypic changes in biomarkers with either changes in the transcriptome or with genetic variants and this is achieved by data integration performed by the CEET Informatics Core. The integration of genomic, proteomic and metabolomics biomarkers offers the promise to deliver new diagnostic and prognostic indicators that can be used for PREcision Environmental Medicine (PREEM) on an individual basis. The TBC is equipped with state-of-the art liquid chromatography-MS, ultraperformance liquid chromatography (UPLC)-MS and UPLC- high resolution MS instrumentation. Many assays use stable-isotope dilution LC-MS as the gold standard for precision and accuracy and many of the assays cannot be performed elsewhere in the world. The goals of the Core are to (i) analyze biomarkers of exposure and effect in biofluids from model systems and in biofluids in population cohorts and patients; (ii) to provide services in discovery and targeted proteomics and metabolomics; (iii) to develop new assays for CEET investigators and translate these assays into routine Core services for other CEET investigators; and (iv) to provide training to end-users who wish to conduct their own analysis.